Our results support the hypothesis that the combination of SHP2 inhibition with ALK inhibition may have therapeutic potential in the treatment of ALK+ NSCLC by specifically targeting cancer cells. The gene discussed is PTPN11; the disease is non-small cell lung carcinoma.